MaxCyte, Inc. Exercise of options and PDMR dealing (2143O)
January 30 2023 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 2143O
MaxCyte, Inc.
30 January 2023
MaxCyte, Inc.
("MaxCyte" or the "Company")
Exercise of options, PDMR dealing and Total Voting Rights
ROCKVILLE, MD, January 30, 2023 - MaxCyte (NASDAQ: MXCT; LSE:
MXCT), a leading commercial cell - engineering company focused on
providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialization, announces that
between 3 January 2023 and 5 January 2023, as per filings lodged
with the SEC, Doug Doerfler, Chief Executive Officer, exercised
options over 30,000 shares of common stock of $0.01 of the Company
("Common Stock") ("Exercise") in aggregate. The 30,000 new shares
of Common Stock issued pursuant to the Exercise ("New Common
Stock"), were sold by Doug Doerfler at a price range between of
$5.04 and $5.13 per Common Stock ("Sale"). The sold shares
represent approximately 0.9% of Doug Doerfler's total equity and
option holdings in the Company's stock capital, respectively.
Following the Exercise, Doug Doerfler holds a further 2,983,680
options over Common Stock. His holding of 333,197 shares of Common
Stock representing 0.3% of the issued stock capital of the Company,
remains unchanged.
The sales and option exercises were effected pursuant to a Rule
10b5-1 trading plan adopted by Doug Doerfler on November 18, 2022
relating solely to the sale of shares acquired from exercise of an
option that expires on November 11, 2024.
Total voting rights
The 30,000 New Common Stock have been admitted to trading on AIM
pursuant to the Block Listing announced by the Company on September
6, 2021. The New Common Stock will rank pari passu with the
existing shares of common stock of the Company and will trade in
the unrestricted line of Common Stock trading under the symbol
MXCT. The total issued stock capital of the Company following the
above will be 102,845,612 shares of common stock. Shareholders in
the Company may use this figure as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
stock capital of the Company.
MaxCyte Contacts:
US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint
Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
UK IR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) technology, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(R),
STx(R) GTx(R) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property
portfolio.
Learn more at maxcyte.com and follow us on Twitter and LinkedIn
.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
----------------------------------------------------------------------------
a) Name Doug Doerfler
-------------------------- ------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- ------------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name MaxCyte, Inc.
-------------------------- ------------------------------------------------
b) LEI 54930053YHXULRFCU991
-------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of $0.01 ordinary shares
the financial instrument,
type of instrument US57777K1060
Identification
code
-------------------------- ------------------------------------------------
b) Nature of the transaction Exercise of options over Common Stock
-------------------------- ------------------------------------------------
c) Price(s) and volume(s) $ 0.04 per Ordinary Share Price(s) Volumes(s)
N/A 1 0,613
N/A 9,153
N/A 10,234
-----------
-------------------------- ------------------------------------------------
d) Aggregated information
- Aggregated volume 30,000
- Price N/A
-------------------------- ------------------------------------------------
e) Date of the transaction 3 to 5 January 2023
-------------------------- ------------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
-------------------------- ------------------------------------------------
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
---------------------------------------------------------------------------
a) Name Doug Doerfler
-------------------------- -----------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -----------------------------------------------
b) Initial notification Initial Notification
/Amendment
-------------------------- -----------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name MaxCyte, Inc.
-------------------------- -----------------------------------------------
b) LEI 54930053YHXULRFCU991
-------------------------- -----------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description of $0.01 ordinary shares
the financial instrument,
type of instrument US57777K1060
Identification
code
-------------------------- -----------------------------------------------
b) Nature of the transaction Sale of Common Stock
-------------------------- -----------------------------------------------
c) Price(s) and volume(s) $ 0.04 per Ordinary Share Price(s) Volumes(s)
$5.13 10,613
$5.07 9,153
$5.04 10,234
-----------
-------------------------- -----------------------------------------------
d) Aggregated information N/A
- Aggregated volume 30,000
- Price $5.08
-------------------------- -----------------------------------------------
e) Date of the transaction 3 to 5 January 2023
-------------------------- -----------------------------------------------
f) Place of the transaction London Stock Exchange - AIM
-------------------------- -----------------------------------------------
, the news service of the London Stock Exchange. RNS is approved by
the Financial Conduct Authority to act as a Primary Information
Provider in the United Kingdom. Terms and conditions relating to
the use and distribution of this information may apply. For further
information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEADFNAEPDEAA
(END) Dow Jones Newswires
January 30, 2023 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
